Showing results (61-70 of 66) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Rheumatology and Therapy|June 8, 2020
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension StudyPeter Nash, Laura C Coates, Alan J Kivitz, et al.The Lancet. Rheumatology|January 26, 2024
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL BalancePeter Nash, Philip J Mease, Dona Fleishaker, et al.The Journal of Infectious Diseases|February 28, 2002
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patientsConstance A Benson, Steven G Deeks, Scott C Brun, et al.Physiological Genomics|June 11, 2009
Distinct and novel SLC26A4/Pendrin mutations in Chinese and U.S. patients with nonsyndromic hearing lossPu Dai, Andrew K Stewart, Fouad Chebib, et al.American Journal of Physiology. Cell Physiology|August 19, 2011
Loss-of-function and gain-of-function phenotypes of stomatocytosis mutant RhAG F65SAndrew K Stewart, Boris E Shmukler, David H Vandorpe, et al.Lancet (London, England)|November 12, 2021
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trialNicolino Ruperto, Hermine I Brunner, Olga Synoverska, et al.Pageof 7